Podcasts about Novo

Novo episódio do Café Com Leite: “A Raposa e a Cegonha”. A raposa arma uma pegadinha com sopa em prato raso… e recebe uma lição elegante da cegonha. A história vira conversa sobre empatia: pensar no corpo e no jeito do outro antes de agir, ajustar “o prato” para todo mundo participar. Descubra o modo cegonha e o semáforo das emoções. Dá o play e ouça com a família! ➡️ Siga o Café Com Leite para mais episódios que divertem, ensinam e inspiram. ....................................................................................................................................................................

O famigerado Direct de setembro aconteceu e foi uma apresentação parruda, com uma hora de duração, que trouxe novidades da celebração de 40 anos de Super Mario e muitos jogos para o primeiro semestre do ano que vem. Dentre os destaques, tivemos Pokemon Pokopia, uma espécie de Dragon Quest Builders de Pokémon, Yoshi and the Mysterious Book e um novo Mario Tennis.Participantes:Guilherme JacobsHeitor De PaolaAssuntos abordados:03:00 - Atualização de Silksong deixa alguns chefes iniciais mais tranquilos10:00 - Nintendo Direct de setembro1:13:00 - Nintendo agora consegue patente de mecânica de pokémon também nos EUA1:20:00 - Os jogos mais vendidos nos 30 anos de PlayStation nos EUA1:29:00 - Rápidas e curtasVenha fazer parte do Discord do Overloadr! Hosted on Acast. See acast.com/privacy for more information.

De um lado, um novo modelo de mainframe totalmente projetado para tirar o melhor da IA. Do outro, um banco acelerando a modernização da sua TI para inovar na jornada digital. O resultado dessa combinação é o que exploramos na conversa com Felipe Lopes Boff, Diretor Vice-Presidente do Banco Mercantil, e Guilherme Salazar, Líder de zStack da IBM Brasil.Este é o segundo episódio da terceira temporada da minissérie BeeYond AI, uma cocriação da The Shift com a IBM Brasil.Confira abaixo outros episódios da minissérieAvanços e impactos dos agentes de IA - Agentes de IA orquestram processos complexos, são autônomos, tomam decisões elaboradas e aprendem com o feedback recebido. Sergio Fortuna, VP de vendas da IBM Brasil, explica por que investir já na tecnologia.A IA como aliada da produtividade. Por que a inovação baseada em dados é tão poderosa quando se soma à inteligência artificial?Transformação sustentável com IA. Como a IA pode apoiar a aceleração da transformação digital e os esforços de sustentabilidade das empresas?Otimizando custos com nuvem híbrida e IA. O que acontece quando a IA entra na equação de FinOps?IA e a personalização do atendimento ao cliente. Porque CX ganhou um “efeito turbo” com uso de Inteligência Artificial.Computação quântica + IA mudam o futuro dos negócios. Uma jornada que está cada vez mais próxima. A The Shift é uma plataforma de conteúdo que descomplica os contextos da inovação disruptiva e da economia digital.Visite o site www.theshift.info e assine a newsletter

In dieser Samstagsfolge von “Alles auf Aktien” reden endlich mal wieder mit dem Compounder-König, mit dem Experten für die Immer-Gewinner-Aktien. Und wir fragen ihn, was denn da los ist mit vielen Firmen, die über Jahrzehnte Erfolg hatten – und von denen viele inzwischen schwächeln. Ist sie womöglich vorbei, die Ära Alleskönner-Aktien? Unser Gast wagt die Deep Dives. Er skizziert ein klares Novo-Nordisk-Szenario, erklärt die SAP-Situation und die neue Lage bei Oracle. Außerdem gibt es die ultimative Analyse zur Lage der Luxus-Titel – zu Ferrari, Hermes und LVMH. Er krönt zwei monopolistische Schaufelhersteller zu seinen persönlichen Favoriten. Und zum Schluss verrät er, worüber er mit seiner Frau redet, seit die Kinder aus dem Haus sind. Ein Gespräch mit Wolfgang Fickus. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: kids' A1C and tech access correlation, first generic GLP-1 for weight loss approved, Metformin cuts long covid risk, Tandem Diabetes & Eversense updates, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Accessibility to modern diabetes technology directly correlates with A1c among children with type 1 diabetes globally. Big, cross-sectional study, conducted in 81 pediatric diabetes centers in 56 countries, found that a greater extent of reimbursement for continuous glucose monitoring (CGM), insulin pumps, glucose meters, and insulin was associated with lower A1c levels. Partha S. Kar, MD, Type 1 Diabetes & Technology lead of the National Health Service England, told Medscape Medical News, “As is now being shown in countries such as UK with widespread uptake of technology, there is now population-wide shift in A1c not seen before.”   He added, “If policymakers are serious about bringing A1c at a population level to sub-7.5% - 8% levels, then without technology it would be incredibly difficult to achieve, in my experience and opinion. Leaving the median A1c of a population at above 7.5%-8% goes with complications so that's a decision regarding investment many will have to make in the near future.”   In an accompanying editorial, Elizabeth R. Seaquist, MD, professor of diabetes, endocrinology, and metabolism and co-director of the Institute for Diabetes, Obesity, and Metabolism at the University of Minnesota, Minneapolis, called it “striking” that access to technology in and of itself was associated with improved glycemic control, given that multidisciplinary team care is also needed to provide education and behavioral or psychological support.     https://www.medscape.com/viewarticle/diabetes-tech-access-linked-a1c-kids-t1d-globally-2025a1000nn6 XX A man with type 1 in Illinois has received the first FDA-approved islet-cell replacement treatment, Lantidra, and  he is now producing his own insulin. The treatment works by restoring the body's beta cells, potentially eliminating the need for insulin injections.   The FDA approved Lantidra (donislecel) in 2023. Lantidra uses donor cells and requires lifelong immunosuppressive drugs.     Lantidra is only available at University of Illinois Chicago Health. Other universities, such as the University of Pennsylvania, continue to do islet cell transplants as part of clinical trials. Early data has shown that a majority of participants in the Lantidra clinical study were able to achieve some level of insulin independence, but it's unclear whether the benefits of donislecel outweigh the treatment's safety risks. Nearly 87 percent of participants reported infection-related adverse events, and post-operation complications included liver lacerations, bruising of the liver (hepatic hematoma), and anemia. One patient died of multi-organ failure from sepsis, which Lantidra maker CellTrans stated was “probably related” to the use of either immunosuppression or study drugs.   In addition, some industry leaders have raised the question of whether it's ethical to commercialize the use of deceased donor islet cells. https://diatribe.org/diabetes-research/first-fda-approved-islet-cell-transplant-performed?utm_campaign=feed&utm_medium=social&utm_source=later   XX Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk's injected Saxenda (liraglutide).   The compound, which is a GLP-1 forerunner of Novo's semaglutide products Ozempic and Wegovy, has been approved by the FDA to treat adults with obesity and those who are overweight and have weight-related medical problems.     Saxenda also is endorsed for pediatric patients ages 12 through 17 who are obese and weigh at least 60 kg (132 pounds). The treatment is for both triggering and maintaining weight loss. Saxenda is not the first GLP-1 drug that is available as a generic. In June of last year, Teva also was the first company to launch a knockoff version of Novo's Victoza, which is the same compound as Saxenda but has been approved only for patients with Type 2 diabetes. Sales of the branded versions of both Victoza and Saxenda have declined significantly in recent years as demand for Novo's semaglutide and Eli Lilly's tirzepatide products have skyrocketed. In addition, marketers of compounded products have been aggressively competing for market share in the GLP-1 space. https://www.fiercepharma.com/pharma/saxenda-knockoff-teva-launches-first-generic-glp-1-obesity   XX Metformin could cut the risk of Long COVID by 64% in overweight or obese adults who started the drug within 90 days of infection. The large observational study, published in Clinical Infectious Diseases, analysed health records of over 624,000 UK adults with COVID-19 between March 2020 and July 2023. Among these, nearly 3,000 patients who began metformin treatment soon after diagnosis were tracked for a year. Compared to non-users, their likelihood of developing Long COVID, defined as persistent symptoms 90 days or more after infection, was dramatically lower. https://www.ndtv.com/health/metformin-cuts-risk-of-long-covid-by-64-why-the-diabetes-pill-is-not-for-everyone-9242332 XX Forty-four percent of people age 15 and older living with diabetes are undiagnosed, so they don't know they have it, according to data analysis published Monday in the journal The Lancet Diabetes & Endocrinology. The study looked at data from 204 countries and territories from 2000 to 2023 in a systematic review of published literature and surveys. “The majority of people with diabetes that we report on in the study have type 2 diabetes,” said Lauryn Stafford , the lead author of the study.   “We found that 56% of people with diabetes are aware that they have the condition,” said Stafford, a researcher for the Institute for Health Metrics and Evaluation. “Globally, there's a lot of variation geographically, and also by age. So, generally, higher-income countries were doing better at diagnosing people than low- and middle-income countries.” People under 35 years were much less likely to be diagnosed if they had diabetes than people in middle age or older. Just “20% of young adults with diabetes were aware of their condition,” Stafford said. https://www.cnn.com/2025/09/08/health/diabetes-undiagnosed-half-of-americans-wellness XX A team of Hong Kong scientists is developing an injectable treatment that could potentially improve blood flow in diabetes patients' feet, in the hopes that it will reduce the need for amputation by rebuilding tissue in the arteries.   They also hope to apply the treatment to peripheral artery disease or PAD, a condition caused by the build-up of fatty deposits in arteries that affect blood circulation in the feet. “Traditional treatments for people suffering from poor blood flow in their legs are stent implantation or bypass surgery, which is invasive,” said Wong, who is also the co-founder of a biotechnology company called NutrigeneAI. He said it was his dream to turn research in the academic field into actual clinical treatments. But he added that the team still needed three to four years for further research on the treatment.   https://www.scmp.com/news/hong-kong/health-environment/article/3324671/hong-kong-scientists-developing-new-blood-flow-treatment-aid-diabetes-patients XX   Tandem Diabetes announces Health Canada authorization for distribution of the Tandem t:slim mobile application for Android and iPhone users. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.1 The app is expected to be available later this year.   The Tandem t:slim mobile app will be available for compatible smartphones in the Apple App Store and Google Play store later in 2025. Once available, Tandem will email eligible customers with instructions on how to download and use the app.  https://www.businesswire.com/news/home/20250904665715/en/Tandem-tslim-Mobile-App-Now-Authorized-by-Health-Canada-for-iPhone-and-Android-Phones   XX Some changes to how the Eversense CGM will be rolled out.. right now it's being distributed by Ascensia Diabetes Care.  Senseonics will take back commercial control of the year long implantable CGM on January 1 in the US and expanding worldwide throughout 2026. The change was a mutual decision, according to the two companies, which said they have signed a memorandum of understanding before a definitive agreement is hammered out by the end of the year. To get started, Senseonics is also set to acquire members of Ascensia's commercial staff—including its CGM president, Brian Hansen, who is slated to become Senseonics' new chief commercial officer. https://www.fiercebiotech.com/medtech/senseonics-retake-eversense-cgm-commercial-control-ascensia-diabetes-care XX Utrecht-based medical device company ViCentra has closed an $85 million Series D round of funding led by Innovation Industries, along with existing investors Partners in Equity and Invest-NL. The round also drew support from EQT Life Sciences and Health Innovations.   The recent capital injection will be used to expand ViCentra's manufacturing capabilities, support regulatory approvals, and strengthen commercial rollout across Europe.   The funds will also be used to launch the next-generation Kaleido 2 patch pump in Europe and prepare for entry into the U.S. market.   The global insulin delivery market is growing quickly due to the increasing number of diabetes cases and demand for effective and user-friendly solutions. The market for insulin pumps is projected to exceed $14 billion by 2034. Patch pumps are the fastest-growing segment, signalling a trend toward compact and wearable devices. And here's where ViCentra is positioned to meet this need, offering a user-friendly, sleek design-led alternative to traditional systems.   Kaleido: design-led insulin delivery Kaleido is the smallest and lightest insulin patch pump developed as a lifestyle product with a particular focus on usability and personalisation.   Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials, and users can select their own favourite aluminium shells from a range of ten preset colour options.   It integrates with Diabeloop's hybrid closed-loop algorithms (DBLG1 and DBLG2) and is compatible with Dexcom CGM sensors, positioning it within the next generation of automated insulin delivery systems.   “Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honours those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve,” said Tom Arnold, Chief Executive Officer at ViCentra.   Improving the quality of life for diabetic patients ViCentra, led by Tom Arnold, is on a mission to improve the lives of those with diabetes.   The company reported that demand for Kaleido in Germany, France, and the Netherlands has already exceeded initial expectations.   ViCentra will present updates on Kaleido at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 15–19, 2025, in Vienna.   The company plans to engage with clinicians, investors, and strategic partners to further its role in the evolving diabetes care landscape.   “ViCentra is redefining insulin pump therapy with a platform that truly centres the user experience – combining clinical performance with design simplicity and wearability,” commented Caaj Greebe, Partner at Innovation Industries. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We're proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.”   https://techfundingnews.com/dutch-vicentra-secures-85m-to-bring-insulin-patch-pump-to-more-markets/ XX Luna Diabetes announces they've raised more than 23-million dollars in early venture capital to help continue clinical trials and build out its capacity. This is the company that wants to offer a night time only, tiny, temporary insulin pump – to supplement insulin pen use. According to the company, more than 80% of the improvements in blood sugar from automated insulin delivery systems occur while the user is sleeping. Luna launched a pivotal trial late last year. https://www.fiercebiotech.com/medtech/nighttime-insulin-patch-pump-maker-luna-diabetes-raises-236m   XX Following 15 days and 150 fingerpricks, they're here. The results of the “9 sensor samba“. And what a set of a results…   Well maybe that's overplaying it a little.   Let's just say that the outcome of this n=1 experiment wasn't quite what I expected. One of the established players came out much worse than expected, while a newcomer did a lot better.   Let's dig in, and take a look at the variation. https://www.diabettech.com/cgm/the-nine-sensor-samba-results-revealed/   XX Hard work and perseverance define ranch life, but one man in eastern Montana takes it to another level. At 90, he's still living independently on the ranch he built from the ground up. Even more remarkable? He's a type 1 diabetic.   Bob Delp still begins each day just like he did decades ago, waking up on his ranch near Richey, Montana.   “I always thought if I could ever get a ranch and run a hundred cows, that's what I wanted to do from the time I was a kid,” said Delp.   He made that dream real, the hard way; after coming home from the army, he taught school, hayed for seven cents a bale and saved every cent he could.     “I worked at it real hard because I always felt like it was going to be part of getting me to that ranch that I always wanted,” said Delp.   He did it all while managing type 1 diabetes, a diagnosis that came with few answers and little hope back in the 1950s.   “The doctors tell me being a type 1 diabetic for 66 years isn't supposed to happen. Back then, it was a real challenge,” added Delp.   Statistically, it's almost unheard of. Fewer than 90 people in the world have lived more than 70 years with type 1 diabetes.     Bob credits his late wife, Donna, for helping him beat the odds.   “She has been key in that I always ate on time.”   They've faced their share of storms, both in health and out on the land. Not long after moving to Richey, a heavy snowstorm nearly tore everything apart just after they'd stepped out for dinner.   “If Donna hadn't said it was time to eat, we wouldn't have made it out of there. I guess that's one time that made me happy to have diabetes. And I think that saved us,” said Delp.     Now, he still checks his blood sugar daily but trusts his hands more than high-tech insulin pumps.   “I'm not satisfied with the sensors they have today. I just don't think they're accurate.”   To many, Bob's survival is extraordinary. To him, it's luck.   “The genes are there already, I can't change that so I guess I would have to say just lots of good luck,” said Delp.     And through it all, optimism has been his compass.   “You might fumble the ball, but if you're determined to be a winner, you'll recover that fumble someday,” said Delp.   He still welds nearly every day. Not because he has to, but because it keeps him going.   “As long as I keep doing something like this, I will not be in the nursing home,” said Delp.   https://www.kfyrtv.com/2025/08/09/against-all-odds-montana-man-thrives-with-type-1-diabetes-90/ XX Today, Dexcom is building on this belief and breaking new ground with the launch of its first open call across the U.S. and Canada in search of the next diabetes advocates—giving people with all types of diabetes a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale in the company's World Diabetes Day campaign (Nov. 14) and beyond.  Who is eligible?: Anyone age 2+ living with all types of diabetes or prediabetes can be nominated by themselves or by someone who knows them. Selected candidates will embody strength, advocacy and pride in living with diabetes or prediabetes. Where and how can I nominate myself or someone I know?: Visit Dexcom.com/WorldDiabetesDay When is the deadline to submit a nomination?: Nominations are open from September 10 through September 19 at 12pm PT. What will the selected candidates experience?:   An invite to participate in a World Diabetes Day photoshoot in Los Angeles to have their unique story featured in Dexcom's World Diabetes Day campaign The ongoing opportunity to attend events, connect with community, and raise diabetes awareness around the world XX The European Association for the Study of Diabetes (EASD) 2025 Annual Meeting will feature major clinical trial results in type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, several new clinical practice guidelines, and much more. The 61st annual EASD meeting will take place on September 15-19, 2025, in Vienna, Austria.   

Charlie Kirk foi morto a tiros enquanto discursava em umevento numa universidade no estado de Utah. Kirk tinha 31 anos e era uma figura central no movimento Make America Great Again. E tem ainda:- França enfrenta protestos contra escolha do novo primeiro-ministro. Entre os mais de 200 mil manifestantes, outra pauta também ganhou força: a renúncia do presidente francês Emmanuel Macron- Naasón Joaquín García, de 56 anos, líder de uma megaigreja mexicana chamada La Luz del Mundo, foi acusado de tráfico sexual nos Estados Unidos e pode pegar prisão perpétua- Pela segunda vez em dois dias, um barco da flotilha dosativistas Greta Thumberg e Thiago Ávila foi atingido por um drone em um porto na Tunísia- Reativação do Ministério do Interior por Milei acontece nomomento em que o presidente de extrema-direita precisa reconstruir pontes com os governadores, após o peronismo ganhar as eleições legislativas em Buenos Aires Vote no Mundo em 180 Segundos clicando aqui Notícias em tempo real nas redes sociais Instagram @mundo_180_segundos e Linkedin Mundo em 180 Segundos Fale conosco através do redacao@mundo180segundos.com.br

A criação de centros de patologia digital para atendimento no Sistema Único de Saúde (SUS) tem como objetivo transformar o acesso ao diagnóstico oncológico no Brasil. Com o uso de inteligência artificial e lâminas digitalizadas, será possível acelerar a emissão de laudos, reduzir gargalos e garantir que pacientes em regiões remotas tenham acesso a especialistas de referência.Neste episódio do podcast Biotech and Health, Laura Murta e Camila Pepe conversam com o médico Vitor Piana, diretor-geral do A.C.Camargo Cancer Center, sobre o projeto do Super Centro para Diagnóstico de Câncer lançado pelo Ministério da Saúde e os impactos da tecnologia na rotina da oncologia brasileira.O convidado explica como funcionará a rede de até oito centros digitais, capazes de processar até mil biópsias por dia, e detalha como a IA pode apoiar patologistas na classificação de tumores, aumentar a eficiência dos laudos e abrir caminho para uma nova era de precisão no diagnóstico.

Analysts left ‘kind of in shock' after Oracle reports eye-popping cloud demand numbers, sending the stock soaring and making Larry Ellison the world's richest man. Buy now, pay later service Klarna starts trading after delaying its IPO.  Plus, Novo Nordisk announces big job cuts. 

O papa Leão XIV deve canonizar em 7 de setembro Carlo Acutis, o santo com chance de parecer mais “gente como a gente” dos últimos tempos. Diferentemente de outros santos de altar que viveram em tempos passados, ele parece bem mais próximo: morreu há menos de 20 anos na Itália, gostava de coisas cotidianas, como Nutella, está em vários vídeos e fotos, tem parentes e amigos conhecidos - a mãe, Antonia Salzano, por exemplo, já deu várias entrevistas. Quem o conheceu diz que sua vida foi um exemplo de como ser especial tendo uma rotina normal: gostava de coisas da sua idade, como esportes e videogame, mas classificava seus dias como uma bênção e pregava o caminho a Deus por meio da oração, da eucaristia e da caridade. O podcast é apresentado por Carolina Ercolin e Luciana Garbin e está disponível em todas as plataformas de áudio.See omnystudio.com/listener for privacy information.

Der er masser at se til for de danske detailinvestorer. Nogle af deres favoritselskaber - Bavarian Nordic, Novo Nordisk og Ørsted - er i ilden. Spørgsmålet er, hvordan man skal forholde sig til købstilbud, kapitaludvidelse og en voldsom kursnedtur. Det diskuterer Millionærklubben denne onsdag formiddag, hvor vi også tager temperaturen på de globale finansmarkeder. Med i studiet er Michael Friis Jørgensen fra HC Andersen Capital, samt direktør i Dansk Aktionærforening Mikael Bak. Med over telefonen får vi Jonas Pallesen, der er med i Millionærklubbens Aktiespil, og som vandt aktiespillet hos Dagbladet Børsen i 2024. Vært: Adam Geil See omnystudio.com/listener for privacy information.

Nota: o ep tem ali um stress com áudio durante um minuto mas depois melhora, juro.BILHETES FREAKSHOW LABS:⁠https://ticketline.sapo.pt/pesquisa?q...⁠CUBINHO, o podcast do colectivo CUBO. António Azevedo Coutinho, Ricardo Maria e Vítor Sá arrancam com a segunda parte deste projecto a três frentes. CUBINHO, um podcast em que se garante boa disposição e alguém a embirrar com o Ricardo.António Azevedo Coutinho https://www.instagram.com/antonioacoutinho/https://twitter.com/antonioacoutinhRicardo Mariahttps://www.instagram.com/ricardotaomaria/https://twitter.com/ricardotaomariaVítor Sáhttps://www.instagram.com/savitorsa/https://twitter.com/savitorsa

Hvor alvorligt er droneangrebet i Polen? Hvad kommer 9000 færre ansatte i Novo til at betyde for virksomheden? Og hvad kan vi forvente af Ursula von der Leyens store tale til Europa-Parlamentet i dag? Dagens værter: Niels Frederik Rickers og Søren Carlsen.

Še drugi poudarki iz oddaje: - Zadrževalnik odpadnih voda v Stari vasi pri Postojni ne opravlja svoje naloge. - V Mariboru občani opozarjajo na divjanje z avtomobili, motorji in e-skiroji. - Po lanski zrušitvi strehe na športni dvorani pri Škofijski gimnaziji se mariborski ravnatelji bojijo, da bi lahko bilo tovrstnih primerov še več. - Prenove osnovne šole, ocenjene na kar 14 milijonov evrov, se bodo v občini Vojnik najverjetneje lotili postopno.

Estamos #NOAR! A consolidação do Bahia, seu reposicionamento no cenário nacional e seus impactos no futebol nordestino. Vem acompanhar tudo com a turma!

Israel ataca membros do Hamas no Qatar. Guterres condena violação da soberania. Mais de 575 mortos nas estradas moçambicanas em 2025. O que está a falhar na segurança rodoviária? Novo programa de alimentação escolar em Angola gera dúvidas nas comunidades.

Comunidade Presbiteriana Chácara Primavera contemporânea • acolhedora • transformadora Nos envie sua dúvida: http://chacara.org/talk http://chacara.org https://facebook.com/chacaraprimavera/ https://instagram.com/chacaraprimavera/

Analytiker og investor spår at nedturen for Ørsted-aktien fortsætter. Novos problemer fortsætter i USA trods FDA-liste. Skæbnedag for energiminister Lars Aagaard i sag om Energinet. 4-procentslånet lukker efter nye rentefald. Arbeiderpartiet bliver igen størst i Norge og Gahr Støre kan fortsætte. Macron står igen i store problemer. Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)  

Qual parte mais te marcou???

Semana tem sido de negócios tímidos no Brasil, com produtores ainda focados em negócios com a soja disponível, e atenção ao clima para fazer a safra nova.

O Governo do Estado de São Paulo realiza mostra da maquete do Novo Centro Administrativo, instalada no térreo do Palácio dos Bandeirantes. A peça, de grandes proporções e riqueza de detalhes, permite ao público visualizar o projeto que reunirá secretarias e órgãos estaduais em um mesmo complexo, ao mesmo tempo em que promove a requalificação do bairro dos Campos Elíseos, marco histórico da capital.

Nous, vous ça fait J+7. Mais ça fait aussi NOVO19, la nouvelle chaîne lancée par Ouest France, vendredi sur la TNT. Bonjour, je m'appelle Arnaud et c'est moi qui fais le résumé cette semaine. Il est peut-être 18h10 à l'heure où vous nous écoutez, j'espère que vous avez passé une bonne journée. Rentrée des talks : rien n'a changé sauf TPMP qui est passé sur W9. Table impertinente : le nouveau JT de Léa Salamé. Record : retour sur le ZEvent 2025. Et dans l'actu, le départ de Castaldi d'Europe 2 et… je suis encore en retard dans mon actu….. Ah oui, pardon, dans l'actu cette semaine : la suspension de Thomas Legrand, le rentrée de Radio France et le petit Mouv', la fausse arrivée de Pierre Lescure à Sud Radio, Stéphane Bern qui visitera probablement Berne en hélico et TF1+ gratuit gratuitement mais aussi gratuit si vous payez. Mais aussi payant. Puis, pêle-mêle, les imitations d'Alex, de l'entre-lêchage, On l'a dans le Q, la moitié de Martin, Emoji Lapix, des melons et des pamplemousses, Dr Feel Good Juice, le poussin Piou, le 22 septembre (merci Hachebaie) et une valise. Le 22 septembre. Merci Hachebaie. Il n'y atoujours pas de replay sur T18. Le 22 septembre pour Mouv'. Merci Hachebaie. Au sommaire : 00:00 - Introduction 15:12 - Vu & Entendu 1:40:07 - L'Actu 2:19:23 - Conclu Recos : YouTube - Sylvqin “J'ai passé mon enfance à voler des Allopass Sources : PureMédias - Audiences : T18 et NOVO19… À quel niveau se situent les deux dernières chaînes nées sur la TNT ? PureMédias - Audiences : Cyril Hanouna a-t-il fait avec “Tout beau, tout n9uf” sur W9 une meilleure rentrée que sur C8 avec “TPMP” l'an passé ? PureMédias - Audiences access 20h : Quel score pour la première de Léa Salamé au “20 Heures” de France 2 ? Arrêt sur images - Léa Salamé au “20 heures” : “Voir des titres type Cnews sur France 2, c'est inquiétant” ZEvent - Site officiel Le Monde - Le Z Event, marathon caritatif des streameurs au modèle économique difficile à reproduire X - Infographie officielle du ZEvent X - Domingo et le BattleBoost Le Monde - Le journaliste Thomas Legrand suspendu par France Inter pour des propos sur Rachida Dati dans une vidéo X - Communiqué Thomas Legrand Libération - Filmés avec des élus du PS, Thomas Legrand et Patrick Cohen se défendent de tout «complot» X - Communiqué SNJ Radio France X - Nouveautés Mouv' X - Mon petit France Inter YouTube - Soirée de rentrée 2025-2026 de Radio France X - Pierre Lescure et Sud Radio Ouest-France « La Carte aux trésors » : Stéphane Bern remplace Cyril Féraud sur France 3 X - Canal+ va racheter UGC Communiqué de presse - TF1+ lance le micro-paiement Rejoignez le Discord d'Alex Arbey, suivez @jplussept sur X/Twitter et sur Instagram ou @jplus7.fr sur Bluesky Laissez-nous vos avis sur ce que vous avez vous aussi vu & entendu tout au long de la semaine sur repondeur.jplus7.fr Une émission animée par Alex Arbey, en direct sur Twitch tous les lundi à 20h35 : twitch.tv/alexarbey

Hoje o Pod Entrar faz uma visita especial à cobertura da atriz Luma Costa!

Novo episódio no ar! E dessa vez, Camila e Natalia mergulham no tema Tecnologia e Feminismo no Brasil.Neste episódio, discutimos o que significa “tecnologia” e como ela atravessa nossas vidas cotidianas, em especial a vida das mulheres brasileiras. Refletimos sobre a possível neutralidade das tecnologias, o impacto do capitalismo de vigilância, e as conexões entre gênero, raça e tecnologia — com foco nos aplicativos de redes sociais.Como as tecnologias moldam nossas relações sociais? Elas podem ser pensadas como neutras ou carregam desigualdades de poder? Quais os riscos e as possibilidades de resistência para mulheres no Brasil?Dá o play e vem refletir com a gente! 

Comunidade Presbiteriana Chácara Primavera contemporânea • criativa • acolhedora • transformadora http://chacara.org https://facebook.com/chacaraprimavera/ https://instagram.com/chacaraprimavera/

Ørsted har en drejebog klar, hvis situationen igen eskalerer. Kongetal viser køligere jobmarked i USA. Ruslands hidtil største angreb mod Ukraine er en bevidst optrapning af krigen. TDC får hård kritik for at ignorere Kina i slagsmål med den danske stat. I dag falder endnu en fransk premier­mi­ni­ster. Trump truer med told efter EU's milliard­bøde til Google. Novo er nu billigere end en gennem­snitlig global aktie.   Vært: Trine Duvander (trine.duvander@borsen.dk)

Agência da ONU apoia ações para conter a 16ª. epidemia registrada no país centro-africano desde 1976; último episódio, em abril de 2022, durou cerca de um mês; 28 casos suspeitos foram confirmados na província congolesa de Kassai.

PL da anistia prevê Bolsonaro livre para disputar Planalto em 2026. Novo terremoto atinge Afeganistão e número de vítimas deve crescer. Neurocientistas divulgam imagens inéditas de cérebro durante tomada de decisão. Concluir Educação de Jovens e Adultos aumenta empregabilidade e renda. Aprenda a fazer o prompt perfeito para se comunicar com a inteligência artificial. E morre Giorgio Armani, ícone da moda, aos 91 anos. Essas e outras notícias, você escuta No Pé do Ouvido, com Yasmim Restum.See omnystudio.com/listener for privacy information.

Novo episódio e dessa vez temos um Chicopapo, quando entrevistamos um praticante da nossa comunidade. Hoje a Ada conversa com a Kono sobre a trajetória dela dentro do BDSM como uma mulher cis gorda e sapatona. A Kono tem 34 anos, nasceu no Chile mas mora no Brasil desde 2016 e contou sobre vivências em diferentes países, seus processos pessoais como uma mulher gorda e sapatão e seus trabalhos, projetos e performances que abordam todo esse universo de sexualidades dissidentes, corporalidade gorda, queer e lesbofeminista.  Participantes: Ada @aleneouada, Kono @lacerdapunkVoz da vinheta: André @thefallenandrew de Santo André, SP Form para envio de dúvidas e feedbacks: https://forms.gle/x3HUheP52BkALn989 Apoie o Chicotadas! https://apoia.se/chicotadasNossos links: https://chicotadas.com.br/Confira nosso Instagram: www.instagram.com/chicotadaspodcast  A vitrine do episódio é uma arte na nova identidade visual do Chicotadas. Com fundo vermelho, as letras, imagens e detalhes são em amarelo claro, lilás e roxo. Ao centro, na parte superior, a palavra “Chicopapo”, com corações nas duas letras “o”, e o nome da entrevistada, Kono. Abaixo do título, duas fotos da Kono, sobre fundo lilás. Em uma das fotos, ela olha para a câmera e usa uma blusa de tecido arrastão rosa e, na outra, está amarrada com cordas vermelhas e de olhos fechados. É possível ver a nova logo do Chicotadas, o desenho de um chicote longo posicionado de forma a lembrar uma onda sonora, e o subtítulo do episódio: Vivência gorda, sapatão e dissidente na comunidade BDSM de diferentes países, processos pessoais, políticos e artísticos, lutas, desafios e aprendizados. Minutagens:1:24 Introdução do episódio e autodescriçãoTexto "Nenhuma ação é essencialmente dominante ou submissa no BDSM". https://www.instagram.com/p/CoVGzcOulSq/4:27 Sobre a Kono e a trajetória dela no BDSM (corpos gordos, dissidentes, desejo fora do normativo, BDSM como busca por lugar onde coubesse,Paul Preciado, bondage, shibari, processo de aprendizado há 10+ anos) 13:14 Sobre ocupar lugares e fazer política (sapatão, sapantão como posicionamento político, entender-se como gorda e sapatão, desejo normativo, Tatiana Nascimento, vídeo Manifesto Gordo, processos na comunidade, autoestima, desejabilidade e merecimento) 29:50 Em que ponto está na sua jornada? (praise kink, adoração, podolatria, exibicionismo, pet play, power trip, visibilidade lésbica, comunidades dissidentes, comunidades de outros países, microcomunidades, Kinky Vibe Argentina @kinkyvibeargentina) 53:35 Como é o espaço para esses corpos atualmente? Sobre padrão, norma e inclusão em eventos e locais. 1:00:38 Recado do Apoia.se https://apoia.se/chicotadas  1:02:35 O que você gostaria que babies sapatão e pessoas gordas soubessem? Recados e conselhos para quem está ouvindo.  1:05:49 Conteúdos e projetos da Kono e indicações - Fanzine Estética Gorde (à venda em Parquinho Gráfico @parquinhografico e Faca Livraria @faca_peluqueria)- "Manifiesto Gordx" (2012)- "Cuerpas e cuerdas" (2015)- Livro "La Cerda Punk" (2014)- Guia de negociação para bottoms (tradução de Kinky Vibes)(Trabalhos linkados em https://www.instagram.com/lacerdapunk/ ) *Kinky Vibes Argentina @kinkyvibeargentina https://linktr.ee/kinkyvibe *Ediyporn (.com) @ediy.p_rn 1:11:05 Encerramento e aftercareVoz da vinheta: André @thefallenandrew de Santo André/SP1:14:25 Erros de gravaçãoNossos links: https://chicotadas.com.br/

O Volkswagen Polo está prestes a viver a maior transformação de sua história. A partir de 2026, o hatch ganha uma versão totalmente elétrica, chamada ID.Polo, com preço abaixo dos 25 mil euros. O modelo estreia na Europa inspirado no conceito ID.2all, com mais espaço interno, baterias de alta eficiência e versões que chegam a 226 cv na variante esportiva GTI. No episódio de hoje, discutimos o impacto dessa virada elétrica do Polo, as diferenças em relação ao modelo a combustão, detalhes de design, autonomia, tecnologia embarcada e as chances de o ID.Polo chegar ao Brasil.

As notícias mais importantes neste começo de manhã.

Essa semana, flipamos altas manobras pelo deserto em Sword of the Sea e corremos contra o relógio no sertão de Hell Clock. Nas notícias, os últimos rumores de um possível PlayStastion 6 portátil, o cheirinho de um novo Dino Crisis, as contratações e rumos do novo estúdio de Hideaki Itsuno e mais! 00:08:23: State of Play de 007 First Light vindo aí 00:14:17: O Playstation 6 terá uma versão portátil? 00:25:04: Pragmata não é Mega Man (é sim) 00:32:20: Novas pistas da volta de Dino Crisis 00:38:33: Novo estúdio de Hideaki Itsuno 00:48:37: Os 10 mais jogados no Steam Deck (agosto de 2025) 00:55:42: Sword of the Sea 01:14:16: Hell Clock 01:31:23: Perguntas dos ouvintes Contribua | Twitter | YouTube | Twitch | Contato

Qual parte mais te marcou?

Cantor foi entrevistado no g1 Ouviu, o podcast e videocast ao vivo de música do g1, nesta quarta-feira (27). No programa, falou de seu novo projeto, contou sobre os bastidores para aprovar 'MTG Quem Não Quer Sou Eu', do DJ Topo, e comentou sobre plano de se dedicar ao teatro.

Novo Nordisk præsenterer stærke resultater for Wegovy til hjertepatienter. Novo-ansattes aktiegaver er tæt på at gå i 0. Onlinesupermarkedet Nemlig vil være profitable og billige. Hjemmearbejde på tilbagetog i finanssektoren viser undersøgelse. Grænser for topskat fastsat fra 2026. Xi, Putin og Modi mødtes i Shanghai. Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)

Novo izvješće otkriva da se broj Australaca koji žive s alergijama u posljednjih 20 godina gotovo udvostručio. Analiza donosi i pregled financijskih i osobnih troškova tog kroničnog stanja. Potražnja za uslugama nikad nije bila veća, a stručnjaci upozoravaju da alergije ne utječu samo na zdravlje – već mogu potpuno preoblikovati život oboljelih.

Du lundi au vendredi, Julien Pichené fait le point sur l'actualité des médias. Aujourd'hui, Maya Lauqué et Damien Thévenot on fait leur première aux commandes de Télématin en semaine, le premier JT de Léa Salamé et NOVO-19 qui commencera à émettre ce soir à 18h. Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Novo episódio no ar!O Podcast Atletas LowCarb chega ao episódio #962 com um tema que divide opiniões, mas que a ciência já deixou bem claro: qual é a dieta mais eficiente para emagrecer de forma consistente e sustentável?Esse episódio nasceu de uma live que foi um verdadeiro sucesso, com uma participação incrível de convidados que trouxeram dados científicos, experiências reais e insights valiosos sobre emagrecimento, metabolismo e adesão a longo prazo.Se você busca clareza em meio a tantas informações contraditórias sobre dietas, esse episódio é para você.Disponível nas principais plataformas de áudio e também em nosso site: www.atletaslowcarb.com.brOuça agora e descubra o que realmente funciona!:: Programa Atletas LowCarb:https://www.atletaslowcarb.com.br/programa-alc/Siga-nos nas redes sociais:Instagram:@atletaslowcarbFacebook:https://www.facebook.com/atletaslowcarb/Site:http://www.atletaslowcarb.com.br

Bom dia 247_ governo Lula bate novo recorde de geração de empregos _28_9_25_ by TV 247

In this episode of Let's Combinate, Subhi Saadeh sits down with Jim Collins, a leader in drug delivery with over 30 years of experience at Eli Lilly, Sanofi, and now as an advisor and board member. Jim shares the history of combination products before the term even existed, from insulin pens in the 1990s to modern platforms and on-body injectors. We cover IP battles that reshaped the industry, supply chain risks that pharma still underestimates, and why platform strategy is one of the most important decisions a company can make today.Timestamps:00:00 – Introduction & Guest Welcome02:00 – Building Lilly's device organization and launching insulin pens06:00 – Early “wild west” days of drug delivery vs. today's structure07:00 – Intellectual property as a competitive weapon10:30 – How Lilly, Novo, and Sanofi shaped the IP landscape13:00 – Device differentiation in the generic space17:00 – Portfolio vs. molecule decisions in platform strategy20:00 – Three reasons to develop your own platform23:00 – Supply chain risk and geopolitical considerations26:00 – Black Swan risks and lessons for pharma companies28:00 – Strategic suppliers vs. transactional vendors33:00 – Drug-device integration inside companies37:00 – Building organizational capability and governance38:00 – Future trends: large volume autoinjectors and connected devices43:00 – Impact of tariffs and supply chain positioning45:00 – Where to find Jim CollinsGuest Bio:Jim Collins is a veteran of the drug delivery field with more than 30 years of leadership experience. At Eli Lilly, he built and led the device organization, overseeing the launch of insulin pens, the Forteo Pen, and the Trulicity platform. Later, at Sanofi, he led drug delivery innovation and platform development, including devices for Dupixent. Today, Jim serves as a board member for Enable Injections and advises startups, helping the next generation of innovators navigate IP, supply chain, and platform strategy.Subhi Bio:Subhi Saadeh is a Quality Professional and host of Let's Combinate. With a background in Quality, Manufacturing Operations, and R&D, he has worked in large medical device and pharma organizations to support the development and launch of hardware devices, disposable devices, and combination products for vaccines, generics, and biologics. Subhi serves as International Committee Chair for the Combination Products Coalition (CPC), as a member of ASTM Committee E55, and previously on AAMI's Combination Products Committee. For questions, inquiries, or suggestions, visit letscombinate.com or connect on LinkedIn.

Novo and Philip (philipchurch.com) discuss the implications of the ever-evolving relationship of art & commerce, how the concept of entertainment fits in, and all their interconnected paradigms, including talks on "The Last of Us," Season 2, furniture, "Back to the Future," Aliens vs. Predator: Requiem, and Rage-Bait Infotainment. Thank you for listening.Please consider supporting us with a donation - @novodeproductions on paypal⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.Support our colleagues at:Philipchurch.comAlexandra-parsons.comCheck out more at www.novodeproductions.com, follow us @_novo_de, @aotb.podcast, @aotbpodcast, and if you'd like to be on the show, you can contact us at novodeproductions@gmail.com.This Episode is also brought to you by:Novel "Til the Bitter [End]emic" - Available now on Amazon. Til The Bitter [End]emic is a novel about discovery; about what we do, who we become, and what we realize is truly important when we're faced with insurmountable odds, the same kind that makes us face our own mortality.Short story - "Cancel Culture Lotto" - available now on Amazon.Zencastr - our go-to tool to record our podcast with multiple guests remotely. With Zencastr, you can record separate audio and video tracks, and it's all backed up on a secured cloud so you never lose your hard work. It's reliable, easy to use, and there's nothing to download. So go to⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠zencastr.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and use promo code: artofthebeholder, and get 30% off your first three months with a PRO account. So create your ⁠⁠⁠⁠⁠⁠⁠podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ today! #madeonzencastr⁠⁠⁠⁠.Note: Only the intro music is by A-CO; all other music or sound effects is stock from various outlets. Main resource for background information: wikipedia.com.